Sunstone Life Science Ventures
Sunstone Life Science Ventures is a European, early-stage VC investing in novel pharmaceutical ingredients for human therapeutic use
Business Model:
Revenue: $10M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Sunstone Life Science Ventures Information
Geographic Data
Address: Lautrupsgade 7
City: Copenhagen
State: other
Zip: 2100
Country: DK
Financial Info
Stage:
Raised Last:
$0
Raised Total:$393M
Social
Facebook
Linkedin
Crunchbase
Metrics
6,683,442Website Global Rank
769Website Monthly Traffic
Twitter Followers
Description
Sunstone Capital is an early-stage life science and technology venture capital company invests in european start-up companies
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2018 | Galecto | Series C | 90.2M |
| 6/2008 | Biomonitor | Venture Round | 4.6M |
| 6/2014 | FBC Device | Venture Round | - |
| 8/2015 | Dubsmash | Series A | 5.5M |
| 12/2014 | Anergis | Series B | 14.9M |
| 12/2010 | Acarix | Seed Round | 6M |
| 2/2016 | Minervax | Venture Round | 2.5M |
| 3/2021 | Ascelia Pharma | Post-IPO Equity | 0 |
| 11/2016 | Dubsmash | Series B | 9.5M |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 6/2012 | Nuevolution | Venture Round | 13.9M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 5/2012 | Egalet | Series B | 14.3M |
| 2/2015 | Prexton Therapeutics | Series A | 10M |
| 2/2014 | Anergis | Series A | 8.9M |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 1/2014 | Minervax | Venture Round | 4M |
| 1/2019 | Minervax | Grant | 5M |
| 7/2010 | Action Pharma | Series C | 6.3M |
| 1/2008 | Action Pharma | Series B | 22M |
| 5/2020 | IO Biotech | Debt Financing | 0 |
| 9/2011 | Orphazyme | Series A | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2023 | Rewind Therapeutics | Series A | - |
| 3/2023 | Teitur Trophics | Series A | 0 |
| 2/2014 | Egalet | Post-IPO Equity | - |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 3/2015 | Rigontec | Series A | 5.2M |
| 12/2020 | Minervax | Series B | 57.6M |
| 12/2022 | Minervax | Series C | 0 |
| 9/2012 | F2G | Equity | 30M |
| 9/2016 | Rigontec | Series A | 16.9M |
| 1/2015 | Orphazyme | Series B | 0 |
| 1/2023 | Rewind Therapeutics | Series B | - |
| 1/2016 | Corti | Pre Seed Round | - |
| 1/2011 | VAXIMM | Venture Round | 8M |
| 6/2016 | F2G | Series E | 60M |
| 3/2017 | Orphazyme | Venture Round | 0 |
| 3/2021 | Step Pharma | Series B | 0 |
| 6/2012 | Adenium Biotech ApS | Venture Round | 1.9M |
| 2/2011 | Orphazyme | Seed Round | - |
| 4/2016 | Anergis | Series C | 5.2M |
| 6/2012 | Santaris Pharma | Venture Round | 12M |
| 7/2013 | Cantargia | Venture Round | 0 |
| 3/2011 | Anergis | Series A | 20M |
| 4/2014 | JenaValve Technology | Series C | 0 |
| 9/2014 | Pulmologix | Venture Round | 12.4M |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 7/2013 | JenaValve Technology | Series C | 62.5M |
| 6/2010 | JenaValve Technology | Series B | 22.7M |
| 2/2022 | TargED Biopharmaceuticals | Series A | 0 |
| 2/2022 | TargED Biopharmaceuticals | Series A | 0 |
| 3/2021 | Step Pharma | Series B | 0 |
| 3/2021 | Ascelia Pharma | Post-IPO Equity | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 12/2020 | Minervax | Series B | 0 |
| 11/2020 | Synendos Therapeutics | Series A | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 5/2020 | IO Biotech | Debt Financing | 0 |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 1/2019 | Minervax | Grant | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
